Trials / Completed
CompletedNCT00044356
Phase II Trial of Allovectin-7® for Metastatic Melanoma
A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Vical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Detailed description
Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7® by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Allovectin-7® |
Timeline
- Start date
- 2001-02-01
- Primary completion
- 2004-08-01
- Completion
- 2004-09-01
- First posted
- 2002-08-28
- Last updated
- 2011-07-07
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00044356. Inclusion in this directory is not an endorsement.